Skip to content
★ Sign in to follow
LP

Louis Ploth Jr.

Repros Therapeutics Inc.
Total declarations
8
Company
1
▲ Purchases (8 ops.)
€42k
▼ Sales (0 ops.)
—

Latest filing published 07 Oct 2008 for REPROS THERAPEUTICS INC., €9,654.

Insider track record

Disclosed buys
8
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
8

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Louis Ploth Jr.: trading record in brief

All filings by Louis Ploth Jr. on record concern Repros Therapeutics Inc. We count 8 filings; the first trade dates from 1 November 2006 and the latest from 7 October 2008.

Every open-market trade on record is a purchase: 8 purchases worth €42k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2008, the count stands at 5 purchases and no sales.

In size, the median ticket on the buying side is €5,095.

The record was last updated on 7 October 2008 with an open-market purchase (€9,654) in Repros Therapeutics Inc. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Louis Ploth Jr.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations8 total
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    14,440 USD0SEC
    2,000 shares@ US$7.22Common StockSEC:0001209191-08-055694:0
    Canonical exit: 5 Jan 2009 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    5,568 USD0SEC
    800 shares@ US$6.96Common StockSEC:0001209191-08-055694:1
    Canonical exit: 5 Jan 2009 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    4,385 USD0SEC
    500 shares@ US$8.77Common StockSEC:0001181431-08-026001:0
    Canonical exit: 21 Jul 2008 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    8,830 USD0SEC
    1,000 shares@ US$8.83Common StockSEC:0001181431-08-025196:0
    Canonical exit: 15 Jul 2008 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    8,680 USD0SEC
    1,000 shares@ US$8.68Common StockSEC:0001181431-08-025196:1
    Canonical exit: 15 Jul 2008 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    6,313 USD0SEC
    1,070 shares@ US$5.90Common StockSEC:0001181431-06-066955:0
    Canonical exit: 1 Mar 2007 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    5,720 USD0SEC
    1,000 shares@ US$5.72Common StockSEC:0001181431-06-066223:0
    Canonical exit: 26 Feb 2007 (T+90)
  • ▲
    VP & Chief Financial OfficerExecutivesRepros Therapeutics Inc.
    7,354 USD0SEC
    925 shares@ US$7.95Common StockSEC:0001181431-06-061274:0
    Canonical exit: 30 Jan 2007 (T+90)

8 of 8 declarations